Mutations of components of the signaling pathway are frequently founded in various cancers.23RAS mutations were detected in 19% of T-ALL patients.24 Ksionda et al25 found that the overexpression of RasGRP1 made Ras/PI3K/Akt signaling pathway respond to oncogenic cytokines by the increases on basic nucleotide exchange of Ras in T-ALL. The gene discussed is RASGRP1; the disease is acute lymphoblastic leukemia.